NeuroSense Therapeutics Ltd. - Warrant

NeuroSense Therapeutics Ltd. - Warrant

Share · IL0011811630 · NRSNW (XNAS)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of NeuroSense Therapeutics Ltd. - Warrant
No Price
27.04.2026 13:30
Current Prices from NeuroSense Therapeutics Ltd. - Warrant
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
NRSNW
USD
27.04.2026 13:30
0,21 USD
-
Company Profile for NeuroSense Therapeutics Ltd. - Warrant Share
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Company Data

Name NeuroSense Therapeutics Ltd. - Warrant
Company NeuroSense Therapeutics Ltd.
Symbol NRSNW
Website https://www.neurosense-tx.com
Primary Exchange XNAS NASDAQ
ISIN IL0011811630
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Alon Ben-Noon
Country Israel
Currency USD
Employees 0,0 T
Address Medinat ha-Yehudim Street 85, 4676670 Herzliya

Ticker Symbols

Name Symbol
NASDAQ NRSNW
More Shares
Investors who hold NeuroSense Therapeutics Ltd. - Warrant also have the following shares in their portfolio:
DZ BANK CLN E.9531
DZ BANK CLN E.9531 Bond
ENGIE 23/53 MTN
ENGIE 23/53 MTN Bond